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Abstract 
Background: The impact of sulfadoxine–pyrimethamine (SP) used as intermittent preventive treatment during preg‑
nancy (IPTp‑SP) on mutant parasite selection has been poorly documented in Burkina Faso. This study sought first to 
explore the relationship between IPTp‑SP and the presence of mutant parasites. Second, to assess the relationship 
between the mutant parasites and adverse pregnancy outcomes.
Methods:  From September to December 2010, dried blood spots (DBS) were collected during antenatal care visits 
and at delivery from 109 pregnant women with microscopically confirmed falciparum malaria infection. DBS were 
analysed by PCR–restriction fragment length polymorphism (PCR–RFLP) for the polymorphisms at codons 51, 59, 108, 
and 164 of the Pfdhfr gene and codons 437 and 540 in the Pfdhps gene.
Results: Both the Pfdhfr and Pfdhps genes were successfully genotyped in 92.7% (101/109) of the samples. The 
prevalence of Pfdhfr mutations N51I, C59R and S108N was 71.3, 42.6 and 64.4%, respectively. Overall, 80.2% (81/101) 
of samples carried the Pfdhps A437G mutation. None of the samples had the Pfdhfr I164L and the Pfdhps K540E 
mutations. The prevalence of the triple mutation N51I + C59R + S108N was 25.7% (26/101). The use of IPTp‑SP was 
associated with a threefold increased odds of Pfdhfr C59R mutation [crude OR 3.29; 95% CI (1.44–7.50)]. Pregnant 
women with recent uptake of IPTp‑SP were at higher odds of both the Pfdhfr C59R mutation [adjusted OR 4.26; 95% 
CI (1.64–11.07)] and the Pfdhfr intermediate‑to‑high resistance, i.e., ≥ 2 Pfdhfr mutations [adjusted OR 3.45; 95% CI 
(1.18–10.07)]. There was no statistically significant association between the presence of the Pfdhfr intermediate‑to‑
high resistance and parasite densities or both maternal haemoglobin level and anaemia.
Conclusion: The data indicate that despite the possibility that IPTp‑SP contributes to the selection of resistant para‑
sites, it did not potentiate pregnancy‑associated malaria morbidity, suggesting the continuation of SP use as IPTp in 
Burkina Faso.
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Background
Malaria during pregnancy persists as a major public 
health challenge with adverse consequences for mother 
and developing fetus [1]. The World Health Organization 
(WHO) has recommended since 2004 relevant strate-
gies, such as the administration of intermittent preven-
tive treatment with sulfadoxine–pyrimethamine during 
pregnancy (IPTp-SP), the use of insecticide-treated nets 
and the effective management of clinical cases to reduce 
the burden of malaria and improve pregnancy outcomes 
[2]. Current policy dictates that SP should be provided to 
mothers at each scheduled focused antenatal care (ANC) 
visit in the second and third trimesters [3]. Although 
IPTp-SP has shown considerable benefits to mother 
and fetus [4], the emergence of Plasmodium falciparum 
resistance to SP can jeopardize this strategy [5].
SP resistance is linked to point mutations in the par-
asite genome, specifically the P. falciparum dihydro-
folate reductase (Pfdhfr) and dihydropteroate synthetase 
(Pfdhps) genes [6, 7]. Mutations in Pfdhfr confer resist-
ance to pyrimethamine while mutations in Pfdhps confer 
resistance to sulfadoxine and other sulfa drugs [8]. The 
more the mutations, the stronger the resistance. The Pfd-
hfr triple mutant (N51I  +  C59R  +  S108N) and Pfdhps 
double mutant (A437G  +  K540E) have been strongly 
associated with potential resistance in sub-Saharan 
Africa [9–12].
The impact of IPTp-SP on selection for drug-resist-
ant parasites in the field is not well understood due to 
reported contradictory results. Indeed, although IPTp-SP 
has been associated with the selection of mutations [10, 
13–15], it has been shown that self-reported use of IPTp-
SP did not increase the prevalence of resistant alleles [5, 
16]. Moreover, conflicting results about the impact of 
mutant parasites on pregnancy outcomes such as para-
site densities, maternal haemoglobin level, and anaemia 
have been reported [14, 15].
In Burkina Faso, IPTp-SP was adopted in 2005 and 
resistance to SP in pregnant women has been only 
reported in rural areas [17, 18], and none of those stud-
ies had assessed the impact of SP on mutant parasites 
selection. Nevertheless, Coulibaly et al. [17] have shown 
that SP remained highly effective in Ziniaré, with a PCR 
corrected failure rate of only 1.3% at 42 days, and a PCR 
uncorrected failure rate of 6.5%. This study sought first, 
to explore the relationship between IPTp-SP and the 
presence of mutant parasites. Second, to assess the rela-
tionship between the mutant parasites and adverse preg-
nancy outcomes, including parasite densities, maternal 
haemoglobin level, and anaemia in Bobo-Dioulasso, the 
second largest city of the country.
Methods
Study area, subjects and sample collection
This study used archived samples collected from two 
malaria-in-pregnancy studies conducted in Bobo-Dioul-
asso from September to December 2010. The study pro-
tocol was approved by the National Ethics Committee for 
Health Research of Burkina Faso. Written informed con-
sent was obtained from all study participants.
Details for these two cross-sectional studies including 
samples collection have been described elsewhere [19, 
20]. Briefly, during these studies, all pregnant women 
presenting for routine ANC or delivery were consecu-
tively recruited at the primary health facilities of Kua 
and Lafiabougou (both located in the peri-urban area 
of Bobo-Dioulasso). Sociodemographic data and infor-
mation about the current and previous pregnancies 
were documented. Iron and folate supplementation and 
SP prophylaxis were given free of charge to all women 
attending ANC at both health facilities. The uptake of 
the drugs was recorded in their antenatal care files, and 
information on the use SP prophylaxis was obtained from 
the pregnant women through questionnaire and from 
these files.
Based on these records, the women were classified as 
IPTp-SP+ if they took at least a first course of IPTp-SP 
and had correctly followed prophylaxis (Fig. 1), or IPTp-
SP− group (control) if they had not received IPTp-SP 
since the beginning of their pregnancy. A finger-prick 
blood sample was collected from each participant for 
preparation of blood smears and blood spots on filter 
paper (Whatman grade 3). Maternal haemoglobin (Hb) 
concentration was measured using a haemoglobinometer 
(HemoCue AB, Angelhom, Sweden).
Laboratory procedures
Molecular genotyping was performed only on samples 
from women with a positive blood slide. All molecu-
lar tests were performed at the West African Centre for 
Cell Biology of Infectious Pathogens, Department of 
Biochemistry, Cell and Molecular Biology, University of 
Ghana, Accra.
Plasmodium falciparum DNA was extracted from dried 
blood spots using QIAamp DNA Mini Kit 50 (QIAgen, 
USA) according to the manufacturer’s recommendations. 
Eluted DNA was immediately used in amplification reac-
tions or was stored at −20 °C until further processing.
SP resistance-mediating single nucleotide polymor-
phisms were analysed in both Pfdhfr and Pfdhps genes 
using polymerase chain reaction (PCR) followed by 
restriction enzyme digestion as previously described [21]. 
Polymorphisms investigated were as follows: N51I, C59R, 
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S108N, and I164L for Pfdhfr gene and A437G and K540E 
for Pfdhps gene. Nested PCR products were resolved by 
2.5% gel electrophoresis and results classified as wild 
type, pure mutant, and mixed infection (presence of both 
wild type and pure mutant in the same sample) on the 
basis of differential band sizes.
Definitions and statistical analyses
Data were double entered in Excel 2013 and analyses per-
formed using STATA 12 (Stata Corp, College Station, TX, 
USA).
Mixed infection was considered as mutant. Infections 
were defined as intermediate-to-high resistance of Pfdhfr 
(≥2 Pfdhfr mutations) if Pfdhfr double and Pfdhfr triple 
mutations were detected [13]. Pregnant women were 
classified into primigravida (first-time mothers) and mul-
tigravida (those with at least one previous pregnancy). 
Age was stratified as ≤20 and >20 years. Recent IPTp-SP 
uptake was defined as receipt of the last SP dose within 
2.5 months of blood sample collection, and early IPTp-SP 
uptake if the interval between last SP dose and the blood 
sample collection was >2.5 months. Anaemia was defined 
as an Hb level lower than 11.0 g/dL [13]. Parasite density 
values were log-transformed for statistical analyses.
Proportions for categorical variables were compared 
using Pearson’s Chi Square test. Comparisons of means 
between groups were done by the Student’s t test, while 
medians were compared by using the Wilcoxon rank-sum 
test.
Logistic regression models were estimated to evaluate 
factors associated with the intermediate-to-high resist-
ance of Pfdhfr and maternal anaemia. Linear regression 
models were used to assess predictors of log-transformed 
parasite densities and maternal Hb. Multivariable analy-
ses were built using backward stepwise regression mod-
els, with an inclusion criterion of P value  <  0.05 and 
exclusion criterion p value > 0.10. Statistical significance 
was set for a P value < 0.05.
Results
Characteristics of study participants
Maternal age, residence and education status were com-
parable between both IPTp-SP+ and IPTp-SP− groups. 
However, primigravida were more frequent in the 
IPTp-SP− group (P =  0.05) compared to the IPTp-SP+ 
group (Table  1). No statistically significant differences 
were found between the IPTp-SP groups in both mater-
nal Hb levels and proportion with anaemia. However, 















≥ 2 IPTp-SP doses
n = 32
Fig. 1 Flow chart of participants through the study
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the median parasite density in the IPTp-SP+ group 
(4080 parasites/μL) was higher than that in the IPTp-SP− 
group (2100  parasites/μL), although this difference was 
not statistically significant (P = 0.06).
Relationship between IPTp‑SP use and the prevalence 
of Pfdhfr and Pfdhps mutations
Overall 101 out of 109 parasite isolates (92.7%) were suc-
cessfully genotyped for both Pfdhfr and Pfdhps genes 
(Fig.  1). The prevalence of the Pfdhfr N51I, C59R and 
S108N mutations was 71.3, 42.6 and 64.4%, respec-
tively. No mutation in the Pfdhfr gene at codon 164 was 
detected in any of the parasite isolates. Pregnant women 
who took the IPTp-SP had lower odds of the Pfdhfr N51I 
mutation compared to those who did not use any IPTp-
SP [crude OR 0.24; 95% CI (0.09–0.62)]. The IPTp-SP+ 
group had greater than threefold increased odds of Pfdhfr 
C59R mutation compared to the IPTp-SP− group [crude 
OR 3.29; 95% CI (1.44–7.50)] (Table  2). In multivariable 
analysis, pregnant women with recent uptake of IPTp-SP 
were at higher odds of carrying the Pfdhfr C59R muta-
tion compared to the early IPTp-SP group [adjusted OR 
4.26; 95% CI (1.64–11.07)]. An additional table shows this 
in more detail (see Additional file 1: Table S1). Consider-
ing the Pfdhfr gene alone, the double mutation (including 
N51I + C59R, N51I + S108N or C59R + S108N) was the 
most prevalent combination, observed in 40.6% (41/101) 
of the isolates. The triple mutation N51I + C59R + S108N 
was found in 25.7% (26/101) of the isolates. The triple 
mutation was more predominant in the IPTp-SP+ group 
(32.6%) than in the IPTp-SP− group (19.2%), however the 
difference was not statistically different (P  =  0.1). With 
regard to Pfdhps gene 80.2% (81/101) of samples car-
ried the A437G mutation. The proportions of the A437G 
mutation in both IPTp-SP groups were statistically similar 
(P = 0.7). No Pfdhps K540E mutation was observed in any 
of the isolates tested.
Overall, 66.3% (67/101) of the isolates carried two or 
more Pfdhfr mutations, classified as the Pfdhfr interme-
diate-to-high resistance. The prevalence of infections 
with at least 2 Pfdhfr mutations was more predominant 
in the IPTp-SP+ group (71.4%) than in the IPTp-SP− 
group (61.5%), however the difference was not statisti-
cally different (P =  0.3) (Table  2). Nevertheless, further 
analysis showed that the uptake of one dose of IPTp-SP 
was significantly associated with the prevalence of infec-
tions with at least 2 Pfdhfr mutations [adjusted OR 5.34; 
95% CI (1.10–26.40)]. An additional table shows this in 
more detail (see Additional file 2: Table S2). In addition, 
in multivariable logistic regression, pregnant women 
with recent uptake of IPTp-SP were at higher odds of 
the Pfdhfr intermediate-to-high resistance compared to 
those who did not use any IPTp-SP [adjusted OR 3.45; 
95% CI (1.18–10.07)] (Table 3). Early receipt of IPTp-SP 
had lower odds of the Pfdhfr intermediate-to-high resist-
ance compared to those who did not use any IPTp-SP 
[adjusted OR 0.61; 95% CI (0.20–1.86)] although this 
association did not reach statistical significance.
Table 1 Baseline characteristics of the study participants
a Pearson Chi square Test
b  Wilcoxon rank-sum test
c  Student’s t test
Characteristic Total (N = 101) IPTp‑SP− (n = 52) IPTp‑SP+ (n = 49) P value
Mean age (years, ±SD) 22.8 ± 5.0 22.1 ± 4.6 23.5 ± 5.3 0.16a
Age group 0.90a
 ≤20 45 (44.5) 23 (44.2) 22 (44.9)
 >20 56 (55.5) 29 (55.8) 27 (55.1)
Education 0.53a
 No formal schooling 67 (66.3) 33 (63.5) 34 (69.4)
 Formal schooling 34 (33.7) 19 (36.5) 15 (30.6)
Gravidity 0.05a
 Primigravida 75 (74.3) 43 (82.7) 32 (65.3)
 Multigravida 26 (25.7) 9 (17.3) 17 (34.7)
Residence 0.10a
 Lafiabougou 43 (42.6) 18 (41.9) 25 (58.1)
 Kua 58 (57.4) 34 (58.6) 24 (41.4)
Median of parasite/μL (IQR) 2960 (5120) 2100 (4140) 4080 (11,080) 0.06b
Mean haemoglobin (g/dL), ±SD 10.3 ± 1.7 10.4 ± 1.7 10.1 ± 1.7 0.30c
Anaemia (% Hb < 11 g/dL) 64 (36.6) 31 (40.4) 33 (32.7) 0.40a
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Effect of the Pfdhfr intermediate‑to‑high resistance 
on maternal outcomes
There was no statistically significant association between 
the presence of the Pfdhfr intermediate-to-high resist-
ance and parasite densities, maternal Hb level and 
prevalence of maternal anaemia (Tables  4, 5). However, 
significant predictors for high parasite densities included 
primigravidae and early IPTp-SP receipt (Table  4). Fur-
thermore, living in the area of the primary health cen-
tre of Kua resulted in a significant increase of 0.90  g/
dL in the maternal Hb level [adjusted regression coeffi-
cient =  0.90; 95% CI (0.24–1.55)] (Table 4) and a lower 
odds of anaemia [adjusted OR 0.35; 95% CI (0.14–0.84)] 
(Table 5).
Discussion
This study analysed samples collected 5  years after 
adoption of IPTp-SP in Burkina Faso. The prevalence 
of Pfdhfr triple mutation N51I + C59R + S108N in the 
present study (25.7%) was low compared to the rates of 
44.9 and 50% reported in pregnant women at the same 
period in Ziniaré [17] and in the general population 
[22], respectively. However, Tahita et  al. [18] reported 
a lower prevalence of 11.4% in pregnant women dur-
ing the same period in Nanoro, a small town in Burkina 
Faso. Those studies had been carried out in rural settings 
Table 2 Prevalence of Pfdhfr and Pfdhps mutations according to IPTp-SP groups
Mutation allele Total (N = 101) IPTp‑SP− (n = 52) IPTp‑SP+ (n = 49) Crude OR 95% CI P value
Pfdhfr N51I 0.003
 No 29 (28.7) 8 (15.4) 21 (42.9) 1
 Yes 72 (71.3) 44 (84.6) 28 (57.1) 0.24 (0.09–0.62)
Pfdhfr C59R
 No 58 (57.4) 37 (71.2) 21 (42.9) 1 0.005
 Yes 43 (42.6) 15 (28.9) 28 (57.1) 3.29 (1.44–7.50)
Pfdhfr S108N
 No 36 (35.6) 22 (42.3) 14 (28.6) 1 0.1
 Yes 65 (64.4) 30 (57.7) 35 (71.4) 1.83 (0.80–4.20)
Pfdhps A437G
 No 20 (19.8) 11 (21.2) 9 (18.4) 1 0.7
 Yes 81 (80.2) 41 (78.8) 40 (81.6) 1.19 (0.45–3.19)
Pfdhfr double mutation 0.7
 No 60 (59.4) 30 (57.7) 30 (61.2) 1
 Yes 41 (40.6) 22 (42.3) 19 (38.8) 0.86 (0.40–1.91)
Pfdhfr triple mutation 0.1
 No 75 (74.3) 42 (80.8) 33 (67.4) 1
 Yes 26 (25.7) 10 (19.2) 16 (32.6) 2.04 (0.82–5.07)
≥2 Pfdhfr mutation 0.3
 No 34 (33.7) 20 (38.5) 14 (28.6) 1
 Yes 67 (66.3) 32 (61.5) 35 (71.4) 1.56 (0.69–3.60)
Table 3 Risk factors associated with the Pfdhfr intermedi-
ate-to-high resistance
a Multivariable analysis using logistic regression adjusted for residence, age, and 
gravidity
Variable N ≥2 Pfdhfr  
mutations (%)
Adjusted OR  
(95% CI)a
P value
Time between last SP dose and the survey
 No IPTp‑SP 52 32 (61.5) 1
 Early IPTp‑SP 19 10 (52.6) 0.61 (0.20–1.86) 0.38
 Recent IPTp‑SP 30 25 (83.3) 3.45 (1.18–10.07) 0.023
Table 4 Predictors of  parasite density and  maternal hae-
moglobin level
a Multivariable analysis using linear regression adjusted for residence, age, and 
Pfdhfr intermediate-to-high resistance
b Multivariable analysis using linear regression adjusted for age, gravidity, education, 
use of IPTp-SP, parasite density, and Pfdhfr intermediate-to-high resistance
Maternal outcome Adjusted coefficient  
(95% CI)
P value
Log10 of parasite density 
(parasite/μl)
 Primigravida 0.35 (0.08 to 0.62)a 0.011
 Early IPTp‑SP 0.30 (−0.01 to 0.60)a 0.05
Haemoglobin level (g/dl)
 Living in Kua 0.90 (0.24 to 1.55)b 0.008
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where malaria transmission is high and seasonal, mainly 
occurring during the months of August–December [17, 
18, 22]. In Burkina Faso, SP had been used as second-
line treatment before 2005, but was increasingly used 
as a first-line drug after chloroquine was discontinued 
in 2005, when artemisinin combination therapy (ACT) 
was not yet readily available [23, 24]. Therefore, those 
different reports suggest either a variation in SP pres-
sure according to study areas or differing access to ACT 
[18]. The prevalence of Pfdhfr triple mutation reported in 
this study was also lower than those previously reported 
during pregnancy in other African countries where the 
proportion of Pfdhfr triple mutation ranged from 36 to 
75% [5, 8, 13, 14, 16, 25]. The Pfdhps A437G mutation is 
very common across Africa [16, 26] and its prevalence 
in this study (80.2%) was higher than the reported rates 
(34.2–75.3%) in other studies conducted during the same 
period in pregnant women from Burkina Faso [17, 18]. 
This difference could be attributed to a variation in the 
level of SP use in different parts of the country, and the 
effect of widespread use of an antibiotic drug, namely 
cotrimoxazole in the population [27]. Indeed, this muta-
tion is involved in resistance to sulfadoxine in endemic 
areas and its selection by SP in pregnant women has been 
recently shown in Cameroon [26]. Both the Pfdhfr I164L 
and the Pfdhps K540E mutations were not detected in 
the present study, suggesting that these are still absent 
in Burkina Faso. This is consistent with previous reports 
in the country [17, 18, 22, 23, 28, 29] as well as in other 
settings in West Africa [8, 13, 14, 25]. However, a low 
proportion of Pfdhps K540E mutation (0.37%) has been 
recently reported in Mali [17].
In accordance with previous reports from Ghana [13] 
and Mali [30], this study showed that the Pfdhfr N51I 
mutation was not selected by the use of IPTp-SP. How-
ever, the use of IPTp-SP was associated with an increased 
prevalence of the Pfdhfr C59R mutation. Significantly, 
IPTp-SP was associated with an increased prevalence of 
both the Pfdhfr C59R mutation and Pfdhfr intermediate-
to-high resistance when SP was expected to be present in 
peripheral blood, i.e., if the last IPTp-SP dose was taken 
within 2.5  months before the blood collection. Further-
more, among pregnant women who benefited from one 
dose of IPTp-SP, more than 70% of them had used IPTp-
SP recently. This is a plausible explanation of the asso-
ciation between the uptake of one dose of IPTp-SP and 
the prevalence of infections with at least 2 Pfdhfr muta-
tions. This is the first study directly implicating the recent 
use of IPTp-SP in the selection of drug resistant parasite 
mutants in pregnant women from Burkina Faso. The 
findings from this study are consistent with those from 
previous studies carried out in Mozambique [10] and 
in Tanzania [15], where it was shown that recent receipt 
of SP was associated with greater prevalence of resist-
ant parasites. This suggests that these resistant parasites 
are no longer competitive during re-infection with other 
strains and that resistance decreases when active drug 
pressure decreases [10, 31]. Several observational studies 
in Africa had shown the association between the use of 
IPTp-SP and the increased prevalence of mutations [13, 
14, 26, 32]. However, those studies did not use the timing 
between the last dose of IPTp-SP and the blood sample 
collection as a proxy to further assess this association.
Higher parasite densities were frequent in pregnant 
women with early receipt of IPTp-SP compared to those 
who did not use any IPTp-SP. After stratification by the 
presence of Pfdhfr intermediate-to-high resistance, this 
association was statistically significant in primigravida 
who harboured parasites with low Pfdhfr grade of resist-
ance. This is not surprising because parasite densities 
decrease due to acquired immunity against malaria para-
sites when parity increases [13]. The use of IPTp-SP was 
not associated with higher parasite densities in Mozam-
bique [10] and in Malawi [11], despite the possibility 
that IPTp-SP contributes to the selection of quintuple 
mutant-resistant parasites. Those findings contrast with 
a report from Tanzania where recent receipt of SP was 
associated with higher parasite densities due to the pres-
ence of Pfdhps mutation at codon 581 in that study [15].
This study showed that the Pfdhfr intermediate-to-high 
resistance was not associated with maternal anaemia and 
maternal Hb level. This is consistent with previous reports 
from Mozambique and Malawi [10, 11]. A plausible expla-
nation is the lack of an effect of the mutations on parasite 
densities [10]. Nevertheless, living in the area of the pri-
mary health centre of Kua was a protecting factor against 
anaemia. Malarial anaemia is usually associated with more 
prolonged infections [33], therefore, it is likely that women 
living nearer to the health centre sought medical attention 
sooner and thus avoided the development of anaemia.
The limitations of this study include the small size of 
the studied population and the cross-sectional approach 
used. A longitudinal study would enable a better assess-
ment of the impact of SP on the selection of mutant para-
sites by comparing the level of drug resistance before and 
after SP use.
Table 5 Risk factors associated with maternal anaemia
a Multivariable analysis using logistic regression adjusted for age, gravidity, 
education, use of IPTp-SP, parasite density, and Pfdhfr intermediate-to-high 
resistance
Variable N Anaemia (%) Adjusted OR (95% CI)a P value
Residence
 Lafiabougou 43 33 (76.7) 1
 Kua 58 31 (53.5) 0.35 (0.14–0.84) 0.018
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Conclusion
The present study provides an update on the prevalence 
of mutations conferring SP resistance 5  years after the 
implementation of the IPTp-SP policy in Burkina Faso. 
SP given for IPTp selects for both Pfdhfr C59R muta-
tion and Pfdhfr intermediate-to-high mutant parasites 
in maternal peripheral blood when SP is still present in 
blood. However Pfdhfr intermediate-to-high resistance is 
not associated with pregnancy-associated malaria mor-
bidity. Altogether, the findings from this study suggest 
that SP may still be efficacious when used as IPTp. Never-
theless, further studies are needed to evaluate the in vitro 
and in vivo efficacy of SP.
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